icd 10 code for iv iron therapy

Full Answer

What is the ICD 10 code for adverse effects of iron?

Adverse effect of iron and its compounds, initial encounter 2016 2017 2018 2019 2020 2021 Billable/Specific Code T45.4X5A is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM T45.4X5A became effective on October 1, 2020.

What is the CPT code for an iron infusion?

Now, talking provider-based coding/billing, if you came to my office as an established patient for an iron infusion only, you would be billed J1756, 96365 and 96366 (if the length of the infusion warrants it). 99211 is incidental to the drug administration code.

What is the criteria for IV iron therapy?

"IV iron therapy is generally reserved for patients with a serum ferritin ≤100 mcg/L, transferrin saturation <45 percent, and either a malabsorption state, complete intolerance to oral iron preparations, moderate to severe symptoms despite a trial of oral iron, or the need for a more rapid response due to severity of symptoms".

What is the role of IV iron supplementation in the treatment of anemia?

Routine supplementation with IV iron usually results in higher hemoglobin and hematocrit values or a decrease in epoetin requirements in patients with anemia and chronic kidney disease. Morbidity and mortality decrease in epoetin-treated patients with chronic renal failure as the anemia improves.

What is the CPT code for IV iron infusion?

96374 is the code for the physician to administer the IV.

What ICD-10 codes cover iron?

E61. 1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM E61.

What is an iron IV treatment?

Iron infusion is a procedure in which iron is delivered to your body intravenously, meaning into a vein through a needle. This method of delivering medication or supplementation is also known as an intravenous (IV) infusion. Iron infusions are usually prescribed by doctors to treat iron deficiency anemia.

What diagnosis will cover iron studies?

Ferritin, iron and either iron binding capacity or transferrin are useful in the differential diagnosis of iron deficiency, anemia, and for iron overload conditions.

What is the code for iron?

LOINC MapOrder CodeOrder Code NameOrder Loinc001339Iron2498-4

What is the ICD-10 code for iron and TIBC?

ICD-10-CM Diagnosis Code D50 D50.

What is the name of IV iron?

DrugTrade (brand) nameFerric carboxymaltose (FCM)Injectafer (United States), Ferinject (United Kingdom and other countries)Ferric derisomaltose (previously called iron isomaltoside)Monoferric (United States, Canada), Monofer (United Kingdom, other countries)Ferric gluconate (FG)Ferrlecit3 more rows

What are the types of iron infusions?

FDA-approved iron infusions include:Feraheme (ferumoxytol). This iron infusion has two FDA-approved uses. ... Ferrlecit (sodium ferric gluconate). ... Injectafer (ferric carboxymaltose). ... Monoferric (ferric derisomaltose). ... Triferic AVNU (ferric pyrophosphate citrate). ... Venofer (iron sucrose).

When do you give iron IV?

IV iron may be needed for those with severe/ongoing blood loss (eg, telangiectasias, varices). Gastric surgery (bypass, resection) that reduces gastric acid may severely impair intestinal absorption of oral iron.

What ICD-10 covers ferritin?

Other specified abnormal findings of blood chemistry The 2022 edition of ICD-10-CM R79. 89 became effective on October 1, 2021.

What is the ICD-10 code for anemia?

Code D64. 9 is the diagnosis code used for Anemia, Unspecified, it falls under the category of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism. Anemia specifically, is a condition in which the number of red blood cells is below normal.

Does Medicare cover iron blood tests?

The usual cause of anemia is an iron deficiency. A doctor may recommend a complete blood count (CBC) test to detect anemia. Medicare Part B covers some medically necessary clinical diagnostic lab services, including a CBC blood test.

Description Information

Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Transmittal Information

11/2000 - Added sodium ferric gluconate complex in sucrose injection for first line treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoeitin therapy. Effective and implementation dates 12/01/2000. (TN 130) (CR 1322)

National Coverage Analyses (NCAs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.

General Information

CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Article Guidance

Palmetto GBA has received inquiries related to the billing and documentation of infusions, injections and hydration fluids. Documentation, medical necessity, and code assignment are very important.

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.

What is intravenous iron?

Intravenous iron products provide supplemental iron, thereby increasing iron and ferritin levels while decreasing the total iron binding capacity. Intravenous iron products are used for the treatment of iron deficiency with or without anemia.

How much iron dextran should I take?

Doses of iron gluconate larger than 125 mg given at one time are not recommended by the manufacturer, whereas iron dextran, although not FDA-approved for doses greater than 100 mg, can be given at one time at doses of 250, 500, and/or 1,000 mg doses, if indicated. Iron sucrose can be given in doses of 100 mg or less.

What is the FPC in iron?

A new parenteral iron formation, ferric pyrophosphate citrate (FPC), has a novel structure that differs from conventional intravenous iron formulations, consisting of an iron atom complexed to one pyrophosphate and two citrate anions.

How long does it take to take a 510 mg dose of Feraheme?

The recommended dose of Feraheme is an initial 510 mg dose followed by a second 510 mg dose 3 to 8 days later. Administer as intravenous infusion in 50-200 mL 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP over at least 15 minutes.

Can you take iron after oral iron failure?

Initially, few patients received intravenous iron after oral iron failure, many received no iron supplementation, and there was high use of blood transfusions. Subsequently, administration of intravenous iron was beneficial.

Is iron deficiency a complication of Roux-en-Y?

DeFilipp et al (2013) noted that iron deficiency is a major post-operative complication of Roux-en-Y gastric bypass surgery. Oral replacement can fail to correct the deficiency. Thus, recourse to parenteral iron administration might be necessary. These researchers evaluated the safety and effectiveness of a standardized 2-g intravenous iron dextran infusion in the treatment of iron deficiency after Roux-en-Y gastric bypass surgery. The setting was a university-affiliated community hospital in the United States. These investigators reviewed the medical records of 23 patients at their institution who had received 2 g of iron dextran intravenously for recalcitrant iron deficiency after Roux-en-Y gastric bypass surgery. They obtained the demographic data and the complete blood count and serum iron studies obtained before treatment and at outpatient visits after infusion. Before treatment, all 23 patients were iron deficient (average ferritin 6 ng/ml) and anemic (average hemoglobin 9.4 g/dL). By 3 months, the average ferritin and hemoglobin had increased to 269 ng/ml and 12.3 g/dL, respectively. The hemoglobin levels remained stable throughout the follow-up period. The iron stores were adequately replaced in most patients. Four patients required a repeat infusion by 1 year, because the ferritin levels had decreased to less than 15 ng/ml. The probability of remaining in an iron replete state was 84.6 % (95 % confidence interval: 78 to 91.2 %). One patient required warm compresses for superficial phlebitis. No other significant adverse events were reported. The authors concluded that intravenous administration of 2 g of iron dextran corrected the anemia and repleted the iron stores for greater than or equal to 1 year in most patients. This therapy is safe, tolerable, efficient, and effective.

Is ferric derisomaltose safe for IDA?

On January 16, 2020, the Food and Drug Administration (FDA) granted approval to ferric derisomaltose (Monoferric) 100 mg/mL for the treatment of iron deficiency anemia (IDA) in adult patients who have an intolerance or had unsatisfactory response to oral iron or patients who have non-hemodialysis dependent chronic kidney disease (NDD-CKD). The safety and efficacy of ferric derisomaltose for treatment of iron deficiency anemia (IDA) were evaluated in two 8-week, randomized, open-label, actively-controlled clinical trials performed in a total of 3050 patients with IDA of different etiology who were randomized to treatment with ferric derisomaltose or iron sucrose. Trial 1 included patients with IDA who had intolerance to oral iron or who had had unsatisfactory response to oral iron or for whom there was a clinical need for rapid repletion of iron stores (Auerbach 2019; NCT02940886). Trial 2 included patients with IDA who had non-dialysis dependent chronic kidney disease (NDDCKD) (Bhandari 2019; NCT02940860). Both trials demonstrated the noninferiority of ferric derisomaltose (Monoferric) for change in hemoglobin from baseline to compared to iron sucrose.